Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015.
Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.
Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015.
Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.
http://www.affibody.com/en/News/News/Affibody-receives-clinical-milestone-from-Daiichi-Sankyo/